3Chang CC,Schur BC,Kampalath B,et al.A novel multiparametric approach for analysis of cytoplasmic immunoglobulin light chains by flow cytometry[J].Mod pathol,2001,14(10):1015-1021.
4Babusikova O,Stevulova L.Analysis of surface and cytoplasmic immunoglobulin light/heavy chains by flow cytometry using a lysed-wholeblood technique:Implications for the differential diagnosis of B-cell malignancies [ J ].Neoplasma,2004,51 (6):422-430.
5Yang Y,Yaccoby S,Liu W,et al.Soluble syndecan-1 promotes growth of myeloma tumors in vivo[J].Blood,2002,100(2):610-617.
6Lin P,Owens O,Tricot G,et al.Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma[J].Am J Clin Pathol,2004,121 (4):482-488.
7Matsui W,Huff CA,Wang QJ,et al.Characterization of clonogenic multiple myeloma cells[J].Blood,2004,103(6):2332-2336.
8Bayer-Garner IB,Sanderson RD,Dhodapkar MV.Syndecan-1 (CD138)immunoreactivity in bone marrow biopsies of multiple myeloma:shed syndecan-1 accumulates in fibrotic regions[ J].Mod Pathol,2001,14(10):1052-1058.
9Tassone P,Goldmacher VS,Neri P,et al.Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138^+ multiple myeloma cells[J].Blood,2004,104(12):3688-3696.
10Robillard N,Pellat-Deceunynck C,Bataille R.Phenotypic characterization of the human myeloma cell growth fraction [ J ].Blood,2005,105(12):4845-4848.
2Dure B G M, Salmon S E. Clinical staging system for multiple myeloma. Cancer, 1975,36: 842- 842.
3Lindstrom F D, Hardy W R. Eberle B J, et al. Multiple myeloma and benign monoclonal gammopathy: differentiation by imounofluorescence of lymphocytes. Ann Intern Med,1973,78: 837 - 837.
4Omede P. Boccadoro M, Collone G, et al. Multiple myeloma increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood, 1990,76:1375 - 1375.
5Bariogie B, Plasma cell mylone-new biological insights and advances in therapy. Blood, 1989,73: 865- 865.
6Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood, 1997; 90:2863 - 2892
7Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood, 1993; 81:2658 - 2663
8Van-Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myaloma express a natural killer cell-associated antigen: CD56(NKH-1; Leu-19). Blood, 1990; 76:377- 382
9Gonzalez M, San Miguel JF, Gascon A, et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol, 1992; 39:84- 89
10Lapena P, Prieto A, Garcia-Suarez J, et al. Increased expression of CD56 and HLA/DR antigens in CD2 + cells from multiple myeloma patients. Am J Hematol, 1994; 46:158- 159
4Ruiz-Arguelles GJ, San Miguel JF. Cell surface markers in multi- ple myeloma[J]. Mayo Clin Proc,1994,69(7) :684.
5Harada H,Kawano MM, Huang N,et al. Phenotypic difference of normal plasma cells from mature myeloma eells[J]. Blood, 1993, 81,2658.
6Van Cardp B, Durie BG, Spier C, et al. Plasma ceils in multiple my eloma express a natural killer-associated antigen: CD56 (NKH-1 ; Leu-19) [J]. Blood,1990,76(2) :377.
7Gonzalez M, San Miguel JF, Gascon A, et al. Increase expression of natural killer-associated and activation antigens in multiple my- elomaFJT. Am J Hematol, 1992,39 : 84.
8Adam C. Immunophenotypic Differentiation Between Neoplastic Plasma Cells in Mature B-Cell Lymphoma vs Plasma Cell Myelo- ma[J]. Am J Clin Pathol,2007 ,127 :176.
9Harada H,Kawano MM, Huang N,et al. Phenotypic difference of normal plasma cells from mature myeloma cells[J]. Blood, 1993, 81 : Z658.
10Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lyric bone lesions in mul :iple myeloma and distinguishes myeloma from monoclonal gam- -nopathy of undetermined significance and lymphomas with plas- "nacytoid differentiation[J]. Am J Pathol, 2002,160 : 1293.
